Multiple Sclerosis Trials

ENER-G MS Trial
Status: Enrollment stopped/Study completed

To determine the effects of Tysabri treatment on fatigue in subjects with relapsing forms of MS as measured by changes in patient-reported.


TYGRIS MS Trial

Status: Enrollment stopped/Follow up enrolled patients

This study includes the data collection r/t patients who have enrolled in ENER-G TRIAL.


BRAVO MS Trial

Status: Enrollment stopped/Follow up enrolled patients

To compare the effect of an investigational daily oral treatment in comparison with a placebo in subjects with relapsing remitting multiple sclerosis.


GALA MS Trial

Status: Enrollment stopped/Follow up enrolled patients.

This study is comparing the efficacy and safety of Copaxone 20mg daily injections versus Copaxone 40mg three times a week injections.


ASSESS MS Trial

Status: Currently enrolling

This study compares the efficacy and safety of Fingolimod (Gilenya) 0.25mg and 0.5mg administered orally once a day with Copaxone injections in patients with relapsing remitting multiple sclerosis (RRMS).


CONCERTO MS Trial

Status: Currently Enrolling

A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by an active treatment period, to evaluate the efficacy, safety and tolerability of two doses of oral administration of laquinimod (0.6 mg/day or 1.2 mg/day) in subjects with relapsing remitting multiple sclerosis (RRMS).


GLACIER MS Trial

Status: Currently Enrolling

An open-label, randomized, multi-center, parallel-arm study to assess the safety and tolerability of Glatiramer acetate 40 mg/mL three times a week compared to 20 mg/mL daily subcutaneous injections in subjects with relapsing remitting multiple sclerosis (RRMS).


PASSAGE MS Observational Study
Status: Currently Enrolling

Long-term, prospective, multinational, parallel-cohort study monitoring safety in patients with MS newly started with fingolimod once daily or treated with another approved disease modifying therapy.


TRANSITION MS Observational Study
Status: In submission/will start Enrolling in August or September 2013

Long-term, prospective, multinational, parallel-cohort study monitoring safety in patients with MS newly started with fingolimod once daily or treated with another approved disease modifying therapy.


RESPOND MS Observational Study
Status: Currently Enrolling

A multicenter, open-label, 12-month observational study evaluating the clinical effectiveness and impact on patient-reported putcomes of oral Tecfidera™ (dimethyl fumarate) delayed-release capsules in patients with relapsing forms of multiple sclerosis after suboptimal response to Glatiramer acetate.


EMD SERONO MS Trial

Status: In submission/enrollment start-up projected for Sep-Oct 2013

Efficacy, safety and tolerability of Plovamer acetate: a phase II, randomized, multi-center study evaluating the efficacy, safety and tolerability of Plovamer acetate to Copaxone in patients with relapsing remitting multiple sclerosis (RRMS).


STRATIFY-2 Observational MS Study

Status: Currently Enrolling

JCV Antibody Program in patients with relapsing multiple sclerosis receiving or considering treatment with Tysabri.

Related Links

Retrieving Data